BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT

....

A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

HONEUR: A Research Platform for Haematology Experts

Accelerated real-world data analysis and evidence sharing

Federated network connectivity, data always stays local

SIX WAYS YOU CAN HARNESS THE POWER OF HONEUR

CLICK TO EXPLORE →

Collaborate with Data Partners

Accelerate patient access to transformational medicines through matched patient cohorts

Demonstrate long-term efficacy of transformational medicines in a real-world setting

Identify treatment patterns and perform disease management studies

Enhance understanding of remaining unmet needs

Improve local reporting

HONEUR
Haematology Outcomes
Network in EURope

Janssen
PHARMACEUTICAL COMPANIES OF
Johnson&Johnson

Collaborate with Data Partners

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Participating in a network like HONEUR creates the opportunity to establish and expand collaborations with other scientific institutes. The power of the network enables data analysis on multiple data sets with new methodological and statistical possibilities.

HONEUR is set up to collect knowledge on haematological malignancies and its disease management. Within the collaboration, the environment for a sound scientific exchange is being established. With multiple partners, HONEUR offers the opportunity to gain knowledge on a rare patient population.

PRACTICAL EXAMPLES:
What are the treatment patterns and outcomes over a 5-year follow up in MM patients with extramedullary disease?

What are the treatment patterns and outcomes in patients with haematological malignancies that experienced COVID-19?

BENEFITS TO DATA PARTNERS:

Data capture from multiple data partners:
to answer common research questions of interest, the results of which could be disseminated in peer-reviewed journals.

Benchmarking of own data sets:
versus others

Quick implementation of studies:
due to availability of data

janssen | PHARMACEUTICAL COMPANIES OF Johnson&Johnson

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Accelerate patient access to transformational medicines through matched patient cohorts

Federated data captured via the HONEUR network, with access to individual patient information, may be used to create matched patient cohorts to contextualise data from single arm clinical trials. Using these data, it is possible to estimate the relative efficacy of the new treatment compared to current standards of care for use in regulatory and reimbursement submissions of innovative haematology treatments.

This would alleviate the need for randomised controlled trials (RCTs) and thereby help accelerate patient access across the region.

Relative efficacy can be measured in terms of intermediate endpoints such as:

• Response rates

• Duration of response

• Time to next treatment/progression

It can also be measured through final clinical endpoints such as overall survival.

PRACTICAL EXAMPLES:
What is the overall survival of patients with relapsed and/or refractory multiple myeloma who received at least three prior lines of therapy including Protease Inhibitor (PI), Immunomodulatory Drug (IMID), and CD38 monoclonal antibody treatment?

BENEFITS TO DATA PARTNERS:

Faster performing studies:
undertake more studies in less time with fewer resources - from many months to just days

Accelerated access to transformational medicines:
reduce the time to registration for innovative therapies such as CAR-T

Authorship on publications:
including abstracts and peer-reviewed publications

Expanded opportunities and increased value of your data:
re-use across a wide range of analytic use cases, including the possibility for sponsored studies to help the long-term sustainability of your data source

janssen | PHARMACEUTICAL COMPANIES OF Johnson&Johnson

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Demonstrate long-term efficacy of transformational medicines in a real-world setting

Clinical trials of transformational medicines typically do not have data on the final clinical outcomes from patients. This is in part due to the small number of events at the time marketing authorisation is granted by the European Commission.

Patient-level data from HONEUR data partners may be used to measure the longer-term (final) clinical outcomes of patients, which could be provided to payers as evidence of relative effectiveness to support outcomes-based, managed entry agreements (MEAs) and risk-sharing schemes.

PRACTICAL EXAMPLES:
Time to next treatments/progression and long-term overall survival over a 5-year period in the real-world vs. predicted overall survival data from clinical trials.

BENEFITS TO DATA PARTNERS:

Outcomes-based MEAs:
potential to speed up patient access to transformational medicines

Authorship on publications:
including abstracts and peer-reviewed publications

Increased value of existing data:
thorough enabling its application across a wide range of analytic-use cases including the possibility of sponsored studies to help the long-term sustainability of your data source

janssen | PHARMACEUTICAL COMPANIES OF Johnson&Johnson

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Identify treatment patterns and perform disease management studies

Another way in which you can utilise the federated data captured via the HONEUR network is to identify potential treatment patterns by:

- Studying patient outcomes from different sequences of treatment to better understand which generates the greatest efficacy, measured in terms of overall survival for patients relative to the costs incurred.

- Better understanding inter- and cross-country comparisons of treatment patterns and the relationship between these and observed patient outcomes.

- Understanding what treatments are administered in the real world to inform which treatments can be deemed relevant comparators in health technology assessments of new haematology treatments. This can also inform appropriate comparator selection in randomised controlled trials (RCTs) for pipeline assets.

PRACTICAL EXAMPLES:
Description of treatment sequences in different countries and associated outcomes, e.g. overall survival.

BENEFITS TO DATA PARTNERS:

Improved knowledge and understanding of treatment sequencing:
through leveraging the collaborative network at a national and international level and understanding what sequence of treatments is most effective at achieving the best outcomes for patients

A better understanding of how patients are managed in a real-world setting:
it will be possible to explore adherence to national and international treatment guidelines therefore enabling clinical audit studies

A better understanding of variations in treatment patterns:
both at inter- and cross-country level as well as the factors influencing such variation

Authorship on publications:
including abstracts and peer-reviewed publications

Increased value of existing data:
thorough enabling its application across a wide range of analytic-use cases including the possibility of sponsored studies to help the long-term sustainability of your data source

janssen | PHARMACEUTICAL COMPANIES OF Johnson&Johnson

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Enhance understanding of remaining unmet needs

Federated data captured via the HONEUR network, with access to individual patient information, may be used to better understand the characteristics of patients (including sub-groups) that are best able to predict a response to treatment.

This data can also identify those patients who do not achieve a response, and the contributing factors underpinning this, to help quantify remaining unmet needs.

PRACTICAL EXAMPLES:
Survival outcomes for patients in countries that do not have access to innovative cancer treatments compared to countries where access is granted.

Survival outcomes for patient sub-groups receiving the current standard of care and analyses of potential factors that possibly explain observed variability.

BENEFITS TO DATA PARTNERS:

Contribute to research and understanding of high unmet need:
to guide the development of new treatments

Improve local reporting

BEING AT THE FOREFRONT OF MODERN HEALTHCARE DATA MANAGEMENT
A faster, more efficient European (and global) research environment and evidence generation framework is not an aspiration - it's happening now. Be a part of this community!

CLICK TO EXPLORE →

Federated data captured via the HONEUR network can be used to support data partners' reporting purposes.

When data partners wish or need to summarise/ analyse their data for reasons like qualifying their institution for certain certifications, cancer reporting obligations or others, HONEUR's structure and standardised tools can help make this process run faster and smoother.

PRACTICAL EXAMPLES:

How many patients were admitted within a given year with relapsed/refractory multiple myeloma?

How many of these received a treatment in a third line setting and what was the outcome?

BENEFITS TO DATA PARTNERS:

Standardised reports:
these can be run from your own data at any time

Supporting other reporting obligations:
you can connect the transformed HONEUR data to other reporting obligations (e.g. cancer registries)

Janssen | PHARMACEUTICAL COMPANIES OF *Johnson&Johnson*